The challenges behind the promise of reimbursement
This article was originally published in Clinica
Executive Summary
From R&D to market approval, funding, clinical and cost-effectiveness assessments, cost-containment in ever tighter national and regional healthcare budgets are part of the minefield that is the medical devices and diagnostics industry. Reimbursement provides certain guarantees in an increasingly competitive and regulated environment. The issue, however, is far from simple. A new study published by Clinica Reports seeks to clarify where the industry stands in the key European and US markets
You may also be interested in...
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.